Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe's Biopharma Sector Could Be In For Bumper Year

Executive Summary

The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.

You may also be interested in...



Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

AstraZeneca's Pipeline Reaps Rewards Of Return To Science

AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?

Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases

The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel